Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Acepromazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 7/20 | 0.88 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.88 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.88 |
| ▸ | SLC6A4 known ✓ | P31645 | 6/20 | 0.88 |
| ▸ | ADRA1A known ✓ | P35348 | 6/20 | 0.88 |
| ▸ | ADRA2A known ✓ | P08913 | 5/20 | 0.88 |
| ▸ | DRD1 known ✓ | P21728 | 5/20 | 0.88 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.88 |
| ▸ | MTOR known ✓ | P42345 | 4/20 | 0.70 |
| ▸ | ADRA2B known ✓ | P18089 | 4/20 | 0.60 |
| ▸ | ADRA2C known ✓ | P18825 | 4/20 | 0.60 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.60 |
| ▸ | HRH1 known ✓ | P35367 | 4/20 | 0.60 |
| ▸ | HTR2B known ✓ | P41595 | 4/20 | 0.60 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.60 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.60 |
| ▸ | ADRB2 known ✓ | P07550 | 2/20 | 0.60 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 1/20 | 0.59 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 0.59 |
| ▸ | EGFR known ✓ | P00533 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acepromazine SCHEMBL21803694 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL30620438 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL204734 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL30616039 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL204733 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL7253707 | 1.00 | CYP2D6 (0.88) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL73018 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL29441481 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL29582179 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 | |
| Acepromazine SCHEMBL28142113 | 0.94 | CYP2D6 (1.00) | CYP2D6CYP1A2HTR1ALMNADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | MEIRAGTX GENE REGULATION LTD (GB) | 2026-04-30 | — | — | US | disclosed |
| EP-3494229-B1 | HIGH THROUGHPUT CELL-BASED SCREENING FOR APTAMERS | MEIRAGTX UK II LTD (GB) | 2023-10-25 | — | — | EP | disclosed |
| US-20230065720-A1 | High Throughput Cell-Based Screening for Aptamers | MeiraGTx Gene Regulation Limited (GB) | 2023-03-02 | — | — | US | disclosed |
| US-11568956-B2 | Methods for identifying inhibitors of amyloid protein aggregation | TREVENTIS CORPORATION (US) | 2023-01-31 | — | — | US | disclosed |
| US-11371077-B2 | High throughput cell-based screening for aptamers | MEIRAGTX UK II LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260117282-A1 | High Throughput Cell-Based Screening For Aptamers | CPSF6, TIA1, UPF1 | HTR1A 4240/4885DRD2 3373/4885SLC6A2 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.